Raphi Levy Executes Planned Sale of DRTS Shares
Chief Financial Officer Raphi Levy sells 17,500 shares of DRTS in a planned transaction.
Key Points
- Raphi Levy, CFO of DRTS, sold 17,500 shares on June 23, 2026, in a planned transaction valued at $167,049.75.
- Shares of DRTS traded near $9.89 on Thursday, with recent analyst ratings maintaining a generally positive outlook.
- Institutional activity saw Hightower Advisors increase its position by 188,440 shares, while UBS Group significantly boosted its holdings by 265,988 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Raphi Levy, the Chief Financial Officer of DRTS, sold 17,500 shares of the company on June 23, 2026. This planned transaction was executed at an average price of $9.55 per share, totaling $167,049.75 in value. Shares of DRTS traded near $9.89 on Thursday.
Other Institutional Activity in DRTS
Institutional investors have been active in DRTS recently. Hightower Advisors, LLC grew its holdings by 188,440 shares, ending with 874,994 shares worth about $6.19 million. Aquamarine Financial (Cayman) Ltd opened a new position with 721,501 shares valued at approximately $5.10 million. Apella Capital, LLC held steady with 382,284 shares, valued at $3.07 million. UBS Group AG significantly increased its stake by 265,988 shares, resulting in a total of 286,688 shares valued at about $2.03 million. Meanwhile, Northcoast Asset Management LLC reduced its position by 10,720 shares, holding 147,138 shares worth $1.04 million.
Insider Buying and Selling at Alpha Tau Medical Ltd.
Raphi Levy has been actively trading DRTS shares. Apart from the recent planned sale on June 23, he sold 32,500 shares on June 3, 2026, at an average price of $10.84. Earlier in the year, Levy executed several planned sales, including selling 10,000 shares on February 25 at $7.4 per share and 15,000 shares on January 13 at $7.09 per share.
Analysts Set New Price Targets
On June 4, 2026, Barclays maintained a 'buy' rating on DRTS with a price target of $17. Piper Sandler, on May 19, held its 'hold' rating with a target of $8. Ladenburg Thalmann and HC Wainwright & Co. both maintained 'buy' ratings with targets of $14 and $15, respectively, in May.
Bottom Line
Raphi Levy's recent planned sale of DRTS shares is a routine insider transaction. DRTS's stock activity and institutional interest suggest ongoing engagement from investors. As always, these transactions are reported after the fact and may not indicate future performance.
Get Alpha Tau Medical Ltd. alerts
New 13F filings, insider trades, and analyst moves on $DRTS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.